tiprankstipranks
BeOne Medicines (ONC)
NASDAQ:ONC
US Market
ONC
BeOne Medicines
RESEARCH TOOLSreports
Want to see ONC full AI Analyst Report?

BeOne Medicines (ONC) Stock Forecast & Price Target

867 Followers
See the Price Targets and Ratings of:

ONC Analyst Ratings

Strong Buy
13Ratings
Strong Buy
12 Buy
1 Hold
0 Sell
Based on 13 analysts giving stock ratings to
BeOne
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ONC Stock 12 Month Forecast

Average Price Target

$393.49
▲(21.50% Upside)
Based on 13 Wall Street analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $393.49 with a high forecast of $436.00 and a low forecast of $333.00. The average price target represents a 21.50% change from the last price of $323.87.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"244":"$244","437":"$437","292.25":"$292.3","340.5":"$340.5","388.75":"$388.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":436,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$436.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":393.4936363636363,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$393.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$333.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[244,292.25,340.5,388.75,437],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,279.68,291.7046153846154,303.72923076923075,315.75384615384615,327.77846153846156,339.8030769230769,351.8276923076923,363.8523076923077,375.87692307692305,387.90153846153845,399.92615384615385,411.9507692307692,423.9753846153846,{"y":436,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,279.68,288.43489510489513,297.1897902097902,305.94468531468533,314.6995804195804,323.4544755244755,332.2093706293706,340.9642657342657,349.7191608391608,358.4740559440559,367.228951048951,375.9838461538461,384.73874125874124,{"y":393.4936363636363,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,279.68,283.78153846153845,287.88307692307694,291.9846153846154,296.0861538461539,300.1876923076923,304.28923076923076,308.39076923076925,312.4923076923077,316.59384615384613,320.6953846153846,324.79692307692306,328.89846153846156,{"y":333,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":245.93,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":245.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":299.01,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":332.04,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.16,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":335.6,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":303.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":345,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":314.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":308.44,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293.86,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":279.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$436.00Average Price Target$393.49Lowest Price Target$333.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on ONC
Michael Schmidt
Guggenheim
Guggenheim
$420
Buy
29.68%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Vaxcyte (NASDAQ: PCVX) and BeOne Medicines (NASDAQ: ONC)
Barclays Analyst forecast on ONC
Etzer Darout
Barclays
Barclays
$409
Buy
26.29%
Upside
Reiterated
06/03/26
Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)
Wolfe Research Analyst forecast on ONC
Kalpit Patel
Wolfe Research
Wolfe Research
$340
Buy
4.98%
Upside
Reiterated
06/03/26
Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)
TD Cowen Analyst forecast on ONC
Yaron Werber
TD Cowen
TD Cowen
$424
Buy
30.92%
Upside
Reiterated
06/02/26
TD Cowen Remains a Buy on BeOne Medicines (ONC)
RBC Capital Analyst forecast on ONC
Leonid Timashev
RBC Capital
RBC Capital
$425→$436
Buy
34.62%
Upside
Assigned
06/02/26
RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)
Truist Financial Analyst forecast on ONC
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX), BeOne Medicines (NASDAQ: ONC) and Autonomix Medical, Inc. (NASDAQ: AMIX)
J.P. Morgan Analyst forecast on ONC
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Analysts Conflicted on These Healthcare Names: BeOne Medicines (NASDAQ: ONC), Moderna (NASDAQ: MRNA) and Danaher (NYSE: DHR)
Jefferies Analyst forecast on ONC
Faisal Khurshid
Jefferies
Jefferies
$290→$333
Hold
2.82%
Upside
Reiterated
05/21/26
Jefferies Reaffirms Their Hold Rating on BeOne Medicines (ONC)
Leerink Partners Analyst forecast on ONC
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$364→$367
Buy
13.32%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)
CMB International Securities Analyst forecast on ONC
Jill Wu
CMB International Securities
CMB International Securities
$392.43
Buy
21.17%
Upside
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: BeOne Medicines (ONC), Alector (ALEC)
Morgan Stanley Analyst forecast on ONC
Sean Laaman
Morgan Stanley
Morgan Stanley
$389→$395
Buy
21.96%
Upside
Reiterated
05/07/26
BeOne Medicines price target raised to $395 from $389 at Morgan StanleyBeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Wells Fargo Analyst forecast on ONC
Yanan Zhu
Wells Fargo
Wells Fargo
$400
Buy
23.51%
Upside
Reiterated
05/07/26
BeOne Medicines (ONC) Gets a Buy from Wells Fargo
Bernstein Analyst forecast on ONC
Rebecca Liang
Bernstein
Bernstein
$412
Buy
27.21%
Upside
Reiterated
03/18/26
Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)
Citi Analyst forecast on ONC
Yigal Nochomovitz
Citi
Citi
$405
Buy
25.05%
Upside
Reiterated
01/13/26
Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on ONC
David Li
Bank of America Securities
Bank of America Securities
$389→$402.2
Buy
24.19%
Upside
Reiterated
11/07/25
BeOne Medicines (ONC) Receives a Buy from Bank of America Securities
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on ONC
Michael Schmidt
Guggenheim
Guggenheim
$420
Buy
29.68%
Upside
Reiterated
06/03/26
Analysts Offer Insights on Healthcare Companies: Repligen (NASDAQ: RGEN), Vaxcyte (NASDAQ: PCVX) and BeOne Medicines (NASDAQ: ONC)
Barclays Analyst forecast on ONC
Etzer Darout
Barclays
Barclays
$409
Buy
26.29%
Upside
Reiterated
06/03/26
Barclays Sticks to Its Buy Rating for BeOne Medicines (ONC)
Wolfe Research Analyst forecast on ONC
Kalpit Patel
Wolfe Research
Wolfe Research
$340
Buy
4.98%
Upside
Reiterated
06/03/26
Wolfe Research Sticks to Its Buy Rating for BeOne Medicines (ONC)
TD Cowen Analyst forecast on ONC
Yaron Werber
TD Cowen
TD Cowen
$424
Buy
30.92%
Upside
Reiterated
06/02/26
TD Cowen Remains a Buy on BeOne Medicines (ONC)
RBC Capital Analyst forecast on ONC
Leonid Timashev
RBC Capital
RBC Capital
$425→$436
Buy
34.62%
Upside
Assigned
06/02/26
RBC Capital Reaffirms Their Buy Rating on BeOne Medicines (ONC)
Truist Financial Analyst forecast on ONC
Gregory Renza
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/02/26
Analysts Offer Insights on Healthcare Companies: Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX), BeOne Medicines (NASDAQ: ONC) and Autonomix Medical, Inc. (NASDAQ: AMIX)
J.P. Morgan Analyst forecast on ONC
Jessica Fye
J.P. Morgan
J.P. Morgan
―
Buy
―
Reiterated
06/02/26
Analysts Conflicted on These Healthcare Names: BeOne Medicines (NASDAQ: ONC), Moderna (NASDAQ: MRNA) and Danaher (NYSE: DHR)
Jefferies Analyst forecast on ONC
Faisal Khurshid
Jefferies
Jefferies
$290→$333
Hold
2.82%
Upside
Reiterated
05/21/26
Jefferies Reaffirms Their Hold Rating on BeOne Medicines (ONC)
Leerink Partners Analyst forecast on ONC
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$364→$367
Buy
13.32%
Upside
Reiterated
05/15/26
Leerink Partners Keeps Their Buy Rating on BeOne Medicines (ONC)
CMB International Securities Analyst forecast on ONC
Jill Wu
CMB International Securities
CMB International Securities
$392.43
Buy
21.17%
Upside
Reiterated
05/07/26
Analysts Are Bullish on These Healthcare Stocks: BeOne Medicines (ONC), Alector (ALEC)
Morgan Stanley Analyst forecast on ONC
Sean Laaman
Morgan Stanley
Morgan Stanley
$389→$395
Buy
21.96%
Upside
Reiterated
05/07/26
BeOne Medicines price target raised to $395 from $389 at Morgan StanleyBeOne Medicines price target raised to $395 from $389 at Morgan Stanley
Wells Fargo Analyst forecast on ONC
Yanan Zhu
Wells Fargo
Wells Fargo
$400
Buy
23.51%
Upside
Reiterated
05/07/26
BeOne Medicines (ONC) Gets a Buy from Wells Fargo
Bernstein Analyst forecast on ONC
Rebecca Liang
Bernstein
Bernstein
$412
Buy
27.21%
Upside
Reiterated
03/18/26
Bernstein Sticks to Its Buy Rating for BeOne Medicines (ONC)
Citi Analyst forecast on ONC
Yigal Nochomovitz
Citi
Citi
$405
Buy
25.05%
Upside
Reiterated
01/13/26
Citi Sticks to Their Buy Rating for BeOne Medicines (ONC)
Bank of America Securities Analyst forecast on ONC
David Li
Bank of America Securities
Bank of America Securities
$389→$402.2
Buy
24.19%
Upside
Reiterated
11/07/25
BeOne Medicines (ONC) Receives a Buy from Bank of America Securities
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines

3 Months
Sean LaamanMorgan Stanley
Success Rate
6/10 ratings generated profit
60%
Average Return
+5.77%
Copying Sean Laaman's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.77% per trade.
1 Year
Yaron WerberTD Cowen
Success Rate
27/36 ratings generated profit
75%
Average Return
+35.14%
Copying Yaron Werber's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +35.14% per trade.
2 Years
Andrew BerensLeerink Partners
Success Rate
16/21 ratings generated profit
76%
Average Return
+31.43%
Copying Andrew Berens's trades and holding each position for 2 Years would result in 76.19% of your transactions generating a profit, with an average return of +31.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ONC Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
3
Buy
18
20
19
24
22
Hold
0
1
1
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
18
21
20
26
26
In the current month, ONC has received 25 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. ONC average Analyst price target in the past 3 months is 393.49.
Each month's total comprises the sum of three months' worth of ratings.

ONC Financial Forecast

ONC Earnings Forecast

Next quarter’s earnings estimate for ONC is $1.65 with a range of $1.08 to $3.54. The previous quarter’s EPS was $1.96. ONC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.
Next quarter’s earnings estimate for ONC is $1.65 with a range of $1.08 to $3.54. The previous quarter’s EPS was $1.96. ONC beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Sales Forecast

Next quarter’s sales forecast for ONC is $1.59B with a range of $1.54B to $1.66B. The previous quarter’s sales results were $1.52B. ONC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.
Next quarter’s sales forecast for ONC is $1.59B with a range of $1.54B to $1.66B. The previous quarter’s sales results were $1.52B. ONC beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ONC has Performed in-line its overall industry.

ONC Stock Forecast FAQ

What is ONC’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines’s 12-month average price target is 393.49.
    What is ONC’s upside potential, based on the analysts’ average price target?
    BeOne Medicines has 21.50% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ONC a Buy, Sell or Hold?
          BeOne Medicines has a consensus rating of Strong Buy which is based on 12 buy ratings, 1 hold ratings and 0 sell ratings.
            What is BeOne Medicines’s price target?
            The average price target for BeOne Medicines is 393.49. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $436.00 ,the lowest forecast is $333.00. The average price target represents 21.50% Increase from the current price of $323.87.
              What do analysts say about BeOne Medicines?
              BeOne Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
                How can I buy shares of ONC?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.